ACADIAN ASSET MANAGEMENT LLC - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 120 filers reported holding CYTOMX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.0%.

Quarter-by-quarter ownership
ACADIAN ASSET MANAGEMENT LLC ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,412
-25.2%
2,646,190
-0.3%
0.01%
-26.3%
Q2 2023$4,562
+13.9%
2,653,5760.0%0.02%
+5.6%
Q1 2023$4,006
-5.6%
2,653,5760.0%0.02%
-14.3%
Q4 2022$4,244
-99.9%
2,653,5760.0%0.02%0.0%
Q3 2022$3,846,000
+14.3%
2,653,576
+44.3%
0.02%
+23.5%
Q2 2022$3,366,000
+42.5%
1,839,226
+107.8%
0.02%
+70.0%
Q1 2022$2,362,000
+32.8%
885,107
+115.2%
0.01%
+42.9%
Q4 2021$1,779,000
-50.1%
411,222
-41.3%
0.01%
-50.0%
Q3 2021$3,565,000
-46.3%
700,990
-33.2%
0.01%
-44.0%
Q2 2021$6,642,000
-9.3%
1,049,139
+10.8%
0.02%
-10.7%
Q1 2021$7,321,000
+62.5%
946,961
+37.7%
0.03%
+64.7%
Q4 2020$4,506,000
+16.3%
687,890
+18.2%
0.02%
+6.2%
Q3 2020$3,873,000
+57.1%
582,215
+96.7%
0.02%
+45.5%
Q2 2020$2,465,000
+18.1%
295,999
+8.7%
0.01%
-8.3%
Q1 2020$2,087,000
+23.3%
272,183
+33.7%
0.01%
+50.0%
Q4 2019$1,692,000
+144.9%
203,542
+117.4%
0.01%
+166.7%
Q3 2019$691,000
-58.9%
93,633
-37.5%
0.00%
-62.5%
Q2 2019$1,682,000
+30.1%
149,842
+24.6%
0.01%
+33.3%
Q1 2019$1,293,000
+11.3%
120,274
+136.4%
0.01%
+20.0%
Q2 2018$1,162,000
-44.3%
50,883
-30.6%
0.01%
-44.4%
Q1 2018$2,086,000
+7093.1%
73,289
+4457.8%
0.01%
Q3 2017$29,000
-54.7%
1,608
-61.1%
0.00%
Q2 2017$64,0004,1320.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 524,763$7,924,0003.84%
Congress Park Capital LLC 123,311$1,862,0002.05%
Perceptive Advisors 2,911,715$43,588,0001.66%
RTW INVESTMENTS, LP 908,586$13,720,0001.28%
HAMILTON LANE ADVISORS LLC 68,753$1,038,0000.91%
HARBOURVEST PARTNERS LLC 79,193$1,196,0000.57%
SPHERA FUNDS MANAGEMENT LTD. 273,151$4,125,0000.46%
Exane Asset Management 50,000$755,000,0000.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 622,548$9,400,0000.38%
Cormorant Asset Management, LP 296,712$4,480,0000.36%
View complete list of CYTOMX THERAPEUTICS INC shareholders